Transjugular intrahepatic portosystemic shunts for hepatorenal syndrome
Por:
Hinojosa-Azaola A., Salas Nolasco O.I., Gonzalez Garay A.G., Chavez-Tapia N.C., Solis Galicia C.
Publicada:
1 ene 2014
Categoría:
Medicine (miscellaneous)
Resumen:
This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the benefits and harms of transjugular intrahepatic portosystemic shunts in patients with liver cirrhosis and hepatorenal syndrome versus sham or no intervention or versus conventional therapies (combination of octreotide, midodrine, terlipressin, norepinephrine, albumin, and paracentesis) to other therapies (pharmacologic therapy). © 2014 The Cochrane Collaboration.
Filiaciones:
Hinojosa-Azaola A.:
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Immunology and Rheumatology, Vasco de Quiroga No.15, Col. Sección XVI, Tlalpan, México D.F., Distrito Federal, Mexico
Salas Nolasco O.I.:
Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán, Department of Nephrology and mineral metabolism, Vasco de Quiroga No.15, Col. Sección XVI, Tlalpan, Mexico D.F., Distrito Federal, Mexico
Gonzalez Garay A.G.:
Instituto Nacional de Pediatria, Methodology Research Unit/Neonatology, Insurgentes Sur 3700 - C, Col. Insurgentes Cuicuilco, Coyoacan, Mexico City, Distrito Federal, Mexico
Chavez-Tapia N.C.:
Medica Sur Clinic and Foundation, Department of Gastroenterology, Puente de Piedra 150, Mexico City, Distrito Federal, Mexico
Solis Galicia C.:
Instituto Nacional de Pediatria (Cochrane Mexico), Insurgentes Sur 3700-C, Mexico City, Distrito Federal, Mexico
|